Pressemitteilung BoxID: 692426 (aap Implantate AG)
  • aap Implantate AG
  • Lorenzweg 5
  • 12099 Berlin
  • Ansprechpartner
  • Marc Heydrich
  • +49 (30) 75019-134

LOQTEQ®: Comparative study of aap osteotomy implant's fatigue strength reveals outstanding characteristics compared with market leader

(PresseBox) (Berlin, ) aap announces that the Archives of Orthopaedic and Trauma Surgery, the official journal of the German-speaking Arthroscopy Association (AGA), have published a new study proving the excellent performance of the LOQTEQ® High Tibial Osteotomy plate.

The LOQTEQ® osteotomy system developed by aap consists of two types of plates to correct malalignment of the upper (femur) and lower leg (tibia) and has been successfully applied for more than a year in Germany and many other countries. In addition to integrating the LOQTEQ® technology, the system is mainly characterised by the lean design of the LOQTEQ® high tibial osteotomy (HTO) plate compared with the market leader's TomoFix™[4] medial tibial osteotomy plate, which was also tested. The design is intended to avoid soft tissue irritation and thereby lead to a relief of the burden on the patient. CE approval to the system was granted in May 2013, followed in November 2013 by the FDA approval for the US market.

In a biomechanical study of its fatigue strength by Petersen[5] et al., aap's LOQTEQ® high tibial osteotomy plate was tested in comparison with the market leader's TomoFix™ medial tibial osteotomy plate. The results of the study have been published online on July 12, 2014 in the Archives of Orthopaedic and Trauma Surgery, published by Springer-Verlag of Berlin and Heidelberg. Their summary states that the "fatigue strength of the LOQTEQ® HTO plate was significantly higher in comparison to TomoFix™. These results justify the clinical use of the LOQTEQ® HTO plate."[6]

The findings of this study confirm yet again the strategy pursued by aap of a strategic alignment to innovations that deliver both clinical and economic benefits. These include ease of handling, ease of implantation and removal, reduced risks for the patient and healthcare cost savings.

aap plans to publish the full quarterly report for Q2 2014 on August 14, 2014.

About High Tibial Osteotomy (HTO)

HTO is an effective surgery for the treatment of knee malalignment to reduce the pain and stiffness from osteoarthritis. Osteoarthritis can develop when the bones of the knee and leg do not line up properly. This can put extra pressure on one side of the knee. Over time, this extra stress can wear away the cartilage that protects the knee joint, causing pain and stiffness. HTO is performed to transfer the body weight from the damaged side of the knee to the preserved normal side. The prevalence of knee osteoarthritis increases with age. The HTO surgery is often used to treat osteoarthritis especially for middle-aged active patients as well as older people are staying active longer and is often used as an alternative treatment to total knee replacement.

Forward-looking statement

This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

[4] TomoFix™ is a registered word mark of Synthes GmbH, Switzerland
[5] Prof. Dr. med. Wolf Petersen is senior consultant at the Klinik für Unfallchirurgie und Orthopädie of the Martin-Luther-Krankenhaus in Berlin, where he is in charge of, inter alia, the annual course on corrective osteotomy.
[6] Petersen, W. et al. (2014) Stability of two angular stable locking plates for open wedge high tibial osteotomy (HTO): TomoFix™ versus LOQTEQ® HTO plate, Archives of Orthopaedic and Trauma Surgery

aap Implantate AG

aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company's products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company's products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap's stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit, or download the Company's investor relations app from the Apple's App Store or Google Play.